Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q3

4483.TEDINET S100SUYD
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥22.3bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥8.5bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥19.5bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥7.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥5.7bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥2.1bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥4.0bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥1.8bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥5.6bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥2.0bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥4.0bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥1.8bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥4.0bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.3bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.0bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥1.3bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥103.6bnat 2023-12-31Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥95.1bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥33.6bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥70.0bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥62.9bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥70.0bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥62.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥17.0bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥2.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥9.4bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥21.8bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥2.4bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥27.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥62.312023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥20.142023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥44.982022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.282022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥60.442023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.912023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥42.662022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥18.452022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio67.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.1%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 71
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥102m
Reconciling Itemsreconcilingrevenue2023-10-01 → 2023-12-31−¥12m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥102m
Reconciling Itemsreconcilingrevenue intersegment2023-10-01 → 2023-12-31−¥12m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥515m
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2023-12-31−¥176m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-10-01 → 2023-12-31¥301m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-12-31¥1.5bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-10-01 → 2023-12-31¥301m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥50m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-12-31¥175m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-10-01 → 2023-12-31¥41m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-12-31¥16.6bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2023-10-01 → 2023-12-31¥6.8bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-12-31¥16.6bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-10-01 → 2023-12-31¥6.8bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥51m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥12m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-12-31¥5.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-10-01 → 2023-12-31¥2.5bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-12-31¥4.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2023-10-01 → 2023-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-12-31¥4.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2023-10-01 → 2023-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2023-10-01 → 2023-12-31¥556m
—segment totalrevenue2023-04-01 → 2023-12-31¥22.4bn
—segment totalrevenue2023-10-01 → 2023-12-31¥8.5bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥22.3bn
—segment totalrevenue external2023-10-01 → 2023-12-31¥8.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥102m
—segment totalrevenue intersegment2023-10-01 → 2023-12-31¥12m
—segment totalsegment profit2023-04-01 → 2023-12-31¥6.7bn
—segment totalsegment profit2023-10-01 → 2023-12-31¥3.1bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥417m
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥227m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-12-31¥2.8bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-10-01 → 2022-12-31¥944m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-12-31¥2.7bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-10-01 → 2022-12-31¥901m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥127m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥43m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-12-31¥310m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-10-01 → 2022-12-31¥118m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥62m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥19m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-12-31¥4.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-10-01 → 2022-12-31¥2.0bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-10-01 → 2022-12-31¥492m
—segment totalrevenue2022-04-01 → 2022-12-31¥19.7bn
—segment totalrevenue2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥19.5bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥189m
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥62m
—segment totalsegment profit2022-04-01 → 2022-12-31¥5.7bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 846
ItemContextValueUnit
Profit loss before tax IFRSPrior1QuarterDuration1773000000JPY
Profit loss before tax IFRSCurrentQuarterDuration1957000000JPY
Income tax expense IFRSPrior1QuarterDuration554000000JPY
Income tax expense IFRSCurrentQuarterDuration630000000JPY
Profit loss IFRSPrior1QuarterDuration1218000000JPY
Profit loss IFRSCurrentQuarterDuration1327000000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration1210000000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration1315000000JPY
Profit loss attributable to non controlling interests IFRSPrior1QuarterDuration8000000JPY
Profit loss attributable to non controlling interests IFRSCurrentQuarterDuration12000000JPY
Profit loss IFRSPrior1QuarterDuration1218000000JPY
Profit loss IFRSCurrentQuarterDuration1327000000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration19.28
Basic earnings loss per share IFRSCurrentQuarterDuration20.14
Diluted earnings loss per share IFRSPrior1QuarterDuration18.45
Diluted earnings loss per share IFRSCurrentQuarterDuration19.91
Profit loss IFRSPrior1YTDDuration2655000000JPY
Profit loss IFRSCurrentYTDDuration3991000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration3000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration3000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration3000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration3000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration0JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-0JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration0JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-0JPY
Other comprehensive income IFRSPrior1YTDDuration3000000JPY
Other comprehensive income IFRSCurrentYTDDuration2000000JPY
Comprehensive income IFRSPrior1YTDDuration2659000000JPY
Comprehensive income IFRSCurrentYTDDuration3993000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration2658000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration3979000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration0JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration13000000JPY
Comprehensive income IFRSPrior1YTDDuration2659000000JPY
Comprehensive income IFRSCurrentYTDDuration3993000000JPY
Profit loss IFRSPrior1QuarterDuration1218000000JPY
Profit loss IFRSCurrentQuarterDuration1327000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration-3000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration-2000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration-3000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration-2000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration1000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration0JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration1000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration0JPY
Other comprehensive income IFRSPrior1QuarterDuration-2000000JPY
Other comprehensive income IFRSCurrentQuarterDuration-1000000JPY
Comprehensive income IFRSPrior1QuarterDuration1216000000JPY
Comprehensive income IFRSCurrentQuarterDuration1325000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass